Akebia Therapeutics, Inc. (AKBA)

Akebia Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	155.55	184.84	51.87	42.93	90.47	149.8
Cash & Short-Term Investments	155.55	184.84	51.87	42.93	90.47	149.8
Cash Growth	13.28%	256.36%	20.84%	-52.55%	-39.61%	-44.25%
Receivables	53.51	47.03	34.37	39.29	40.28	55.89
Inventory	13.02	15.61	16.24	15.69	21.57	36.63
Prepaid Expenses	-	-	4.03	14.49	15.62	28.83
Restricted Cash	1.71	1.7	-	-	-	-
Other Current Assets	5.77	3.77	7.32	5.75	17.25	-
Total Current Assets	229.55	252.96	113.83	118.15	185.18	271.15
Property, Plant & Equipment	7.31	4.89	10.42	16.05	34.37	40.61
Goodwill	59.04	59.04	59.04	59.04	59.04	59.04
Other Intangible Assets	-	-	-	36.04	72.08	108.13
Other Long-Term Assets	53.75	59.68	37.38	12.42	5.37	50.42
Total Assets	349.66	376.57	220.67	241.7	356.05	529.35

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	9.42	21.19	15.18	14.64	18.02	33.59
Accrued Expenses	89.65	92.13	33.27	42.94	53.92	97.51
Current Portion of Long-Term Debt	36.93	19.02	4.31	19.55	32	97.54
Current Portion of Leases	1.01	3.55	5.4	4.49	4.74	4.8
Current Unearned Revenue	6.17	2.68	-	-	3.74	20.91
Other Current Liabilities	17.69	24.38	22.75	18.26	17.12	6.7
Total Current Liabilities	160.87	162.94	80.91	99.87	129.54	261.05
Long-Term Debt	156.86	176.21	175.47	111.29	91.56	53.08
Long-Term Leases	4.4	-	3.55	8.95	28.96	33.7
Long-Term Unearned Revenue	-	-	-	43.3	43.3	21.47
Other Long-Term Liabilities	2.52	4.8	9.93	8.89	57.47	86.03
Total Liabilities	324.64	343.96	269.86	272.29	350.82	455.34

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0	0	0	0	0	0
Additional Paid-In Capital	1,727	1,716	1,629	1,578	1,562	1,537
Retained Earnings	-1,702	-1,684	-1,678	-1,609	-1,557	-1,463
Comprehensive Income & Other	0.01	0.01	0.01	0.01	0.01	0.01
Shareholders' Equity	25.02	32.61	-49.19	-30.58	5.23	74.01
Total Liabilities & Equity	349.66	376.57	220.67	241.7	356.05	529.35

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	199.19	198.78	188.73	144.28	157.27	189.13
Net Cash (Debt)	-43.64	-13.94	-136.86	-101.35	-66.8	-39.33
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-0.16	-0.05	-0.65	-0.54	-0.37	-0.24
Filing Date Shares Outstanding	277.11	267.88	236.23	209.37	184.25	181.23
Total Common Shares Outstanding	271.74	265.42	224.85	194.58	184.14	177
Working Capital	68.69	90.02	32.92	18.28	55.65	10.1
Book Value Per Share	0.09	0.12	-0.22	-0.16	0.03	0.42
Tangible Book Value	-34.03	-26.43	-108.23	-125.67	-125.9	-93.16
Tangible Book Value Per Share	-0.13	-0.10	-0.48	-0.65	-0.68	-0.53
Machinery	-	-	-	-	-	5.85
Leasehold Improvements	-	-	-	-	-	8.57

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Aug 5, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 19, 2026

Data Sources Report a data error